Pfizer (PFE) — The Transparent Read
40/100Cautiously Bearish$24.37 · mixed
This is a tug-of-war between a soft technical picture and a genuinely favorable macro backdrop. The price action says caution — below both major averages with fading momentum — but the historical base rate is the kind of data point I respect: 74% higher with a +6.3% median over 90 days is a meaningful edge, not noise. My lean is mildly constructive on a 90-day horizon, but I'd want to see the stock prove itself near-term. Patience over chasing — let it stabilize near support before getting aggressive.
PFE key levels
Show Your Work — every point in PFE's score
The score starts at 50, then each signal below adds or subtracts points. No black box.
| Signal | Type | Points |
|---|---|---|
| Below 200-day MA Price is below its 200-day average — long-term trend is down. | technical | -8 |
| Below 50-day MA Trading below the 50-day average — medium-term momentum is weak. | technical | -5 |
| Golden cross 50-day average is above the 200-day (golden cross). | technical | +4 |
| RSI neutral RSI is 37 — neither overbought nor oversold. | technical | -1.27 |
| MACD negative MACD is below its signal line — momentum is fading. | technical | -5 |
| Macro regime base rate In 38 past periods like today (Rising inflation + Steady Fed), this stock was higher 90d later 74% of the time (median +6.3%). Historically favorable. | macro | +4.74 |
Macro regime base rate
Today's regime: Rising inflation + Steady Fed
In 38 past periods that looked like today, PFE was higher 90 days later 74% of the time (median move 6.3%). Confidence: high.
The read
PFE: Bruised Technicals, But the Macro Tailwind Is Hard to Ignore
Bull case. The macro setup is the standout positive here. In 38 analogous periods of rising inflation and a steady Fed, PFE was higher 90 days later 74% of the time with a median gain of +6.3% — and that's a high-confidence read. The 50-day MA still sits above the 200-day (golden cross), meaning the longer-term structure hasn't fully broken down. At an RSI of 37, the stock is closer to washed-out than overheated, and price is holding well above support at $23.62 — there's room for a bounce.
Bear case. The near-term tape is weak. Price at $24.37 is below both the 50-day ($25.78) and 200-day ($25.24) moving averages, telling you both medium- and long-term momentum are leaning down. The MACD histogram is negative at -0.17 with MACD below its signal line — momentum is fading, not building. The composite score of 39.5/100 lands squarely in Cautiously Bearish territory, and there's a wall of resistance up at $26.49 that any rally has to overcome.
What would change my mind. A decisive close below support at $23.62 would invalidate the constructive case — that breaks the floor and signals the bearish technicals are winning out over the macro tailwind. On the upside, a reclaim of the 50-day MA at $25.78 would flip the medium-term momentum story and confirm the base-rate thesis is playing out.
PFE — frequently asked
Is PFE a buy according to Tallyread?
Tallyread does not give buy or sell recommendations. It shows a transparent 40/100 read for Pfizer (PFE), conditioned on today's macro regime, with every scoring input itemized so you can judge for yourself. This is not financial advice.
How is PFE's Tallyread score calculated?
The 40/100 score starts at 50, then adds and subtracts named technical and macro signals — each shown with its point value and a one-line reason in the "Show Your Work" table on this page. Nothing is hidden in a black box.
How does today's Fed-and-inflation regime affect PFE?
In 38 past periods whose macro regime matched today's (Rising inflation + Steady Fed), PFE was higher 90 days later 74% of the time, with a median move of 6.3%. Confidence: high.
Want a fresh read on PFE with the live chart and macro tape?
Run a live PFE read →Last analyzed 2026-06-30 · Data source: tiingo. See the public scorecard and methodology.
This is a historical and technical read for informational and educational purposes only — not financial advice, and not a recommendation to buy or sell PFE. Markets are uncertain; do your own research.